2024
Medical comorbidities and lower myelin content are associated with poor cognition in young adults with perinatally acquired HIV
Patel P, Prince D, Bolenzius J, Ch’en P, Chiarella J, Kolind S, Vavasour I, Pedersen T, Levendovszky S, Spudich S, Marra C, Paul R. Medical comorbidities and lower myelin content are associated with poor cognition in young adults with perinatally acquired HIV. AIDS 2024, 38: 1932-1939. PMID: 39110577, PMCID: PMC11524773, DOI: 10.1097/qad.0000000000003989.Peer-Reviewed Original ResearchPoor cognitionCognitive impairmentHorizontally acquired HIVMarkers of cognitive reserveAssociated with poorer cognitionRisk factorsCross-sectional studyYoung adultsLower cognitive scoresYears of educationMultiple cognitive domainsExperience cognitive deficitsCognitive domain scoresHIV-uninfected controlsOlder adultsCorticospinal tractCognitive batteryDomain scoresMedical comorbidityCognitive deficitsCognitive domainsMyelin contentCognitive reserveNeuroimaging dataCognitive scores
2023
Brain volumetrics differ by Fiebig stage in acute HIV infection
Bolzenius J, Sacdalan C, Ndhlovu L, Sailasuta N, Trautmann L, Tipsuk S, Crowell T, Suttichom D, Colby D, Phanuphak N, Chan P, Premeaux T, Kroon E, Vasan S, Hsu D, Valcour V, Ananworanich J, Robb M, Ake J, Pohl K, Sriplienchan S, Spudich S, Paul R. Brain volumetrics differ by Fiebig stage in acute HIV infection. AIDS 2023, 37: 861-869. PMID: 36723491, PMCID: PMC10079583, DOI: 10.1097/qad.0000000000003496.Peer-Reviewed Original ResearchConceptsAcute HIV infectionNucleus accumbensFiebig stagesAcute infectionHIV infectionCaudate nucleusBrain volumeLower regional brain volumesAntiretroviral therapy initiationMarkers of neuroinflammationBrain volume alterationsCross-sectional studyRegional brain volumesT1-weighted scansTherapy initiationChronic infectionBrain volumetricsBrain disruptionThai malesViral factorsPutamenVolume alterationsAccumbensInfectionStimulant useHIV-1 is Transported into the Central Nervous System by Trafficking Infected Cells
Kincer L, Schnell G, Swanstrom R, Miller M, Spudich S, Eron J, Price R, Joseph S. HIV-1 is Transported into the Central Nervous System by Trafficking Infected Cells. Pathogens And Immunity 2023, 7: 131-142. PMID: 36865569, PMCID: PMC9973728, DOI: 10.20411/pai.v7i2.524.Peer-Reviewed Original ResearchBlood-cerebrospinal fluid barrierBlood-brain barrierCentral nervous systemHIV-1Cerebrospinal fluidInfected cellsCSF samplesNervous systemCo-infected participantsHCV viral loadHIV-1 replicationCross-sectional studyMigration of HIVHIV-1 particlesHIV-1 populationsBlood plasmaHCV concentrationAntiviral regimensViral loadHCV entryInflammatory responseFluid barrierHCVVirus entryNormal surveillance
2018
CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection
Gisslén M, Heslegrave A, Veleva E, Yilmaz A, Andersson LM, Hagberg L, Spudich S, Fuchs D, Price RW, Zetterberg H. CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. Neurology Neuroimmunology & Neuroinflammation 2018, 6: e512. PMID: 30568991, PMCID: PMC6278890, DOI: 10.1212/nxi.0000000000000512.Peer-Reviewed Original ResearchConceptsHIV-1 infectionHIV-negative controlsMicroglial activationNeuronal injuryCSF concentrationsUntreated HIV-1-infected patientsHIV-1 disease severityHIV-1-infected adultsMacrophage/microglial activationHIV-1-infected patientsRetrospective cross-sectional studyUntreated HIV-1 infectionCNS immune activationCSF sTREM2 levelsSuppressive antiretroviral treatmentT-cell countsMicroglial activation markersT cell lossLevels of CSFNeurofilament light proteinCross-sectional studyCSF sTREM2STREM2 levelsAntiretroviral treatmentActivation markers
2017
Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection
Peluso MJ, Valcour V, Phanuphak N, Ananworanich J, Fletcher JL, Chalermchai T, Krebs SJ, Robb ML, Hellmuth J, Gisslén M, Zetterberg H, Spudich S. Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. AIDS 2017, 31: 247-252. PMID: 27819802, PMCID: PMC5844231, DOI: 10.1097/qad.0000000000001314.Peer-Reviewed Original ResearchConceptsChronic HIV-1 infectionCombination antiretroviral therapyCerebrospinal fluid (CSF) YKL-40Group of HIVHIV-1 infectionYKL-40Treatment initiationUntreated chronic HIV-1 infectionMedian YKL-40Early HIV infectionCSF YKL-40Chemokine ligand 10Neurofilament light chainCross-sectional studyMann-Whitney testAntiretroviral therapyHIV neuropathogenesisMicroglial activationHIV infectionPrognostic valueChi groupMicroglial cellsAHI groupImmediate initiationBlood sampling
2016
Corrigendum to: “Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study” [EBioMedicine 3 (216) 135–140]
Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H. Corrigendum to: “Plasma concentration of the neurofilament light protein (NFL) is a biomarker of CNS injury in HIV infection: A cross-sectional study” [EBioMedicine 3 (216) 135–140]. EBioMedicine 2016, 7: 287-288. PMID: 27322482, PMCID: PMC4909478, DOI: 10.1016/j.ebiom.2016.04.021.Peer-Reviewed Original Research
2015
Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study
Gisslén M, Price RW, Andreasson U, Norgren N, Nilsson S, Hagberg L, Fuchs D, Spudich S, Blennow K, Zetterberg H. Plasma Concentration of the Neurofilament Light Protein (NFL) is a Biomarker of CNS Injury in HIV Infection: A Cross-Sectional Study. EBioMedicine 2015, 3: 135-140. PMID: 26870824, PMCID: PMC4739412, DOI: 10.1016/j.ebiom.2015.11.036.Peer-Reviewed Original ResearchConceptsNeurofilament light proteinHIV-associated dementiaCSF NFL concentrationsCNS injuryHIV infectionNfL concentrationsPlasma concentrationsCSF neurofilament light proteinNeurofilament light chain proteinSingle molecule array immunoassayHIV-negative controlsUntreated HIV infectionReliable blood biomarkersCross-sectional studySimilar age-related increasesAge-related increaseResearch settingsNFL changesHIV-negativeViral suppressionNeuronal injuryAntiretroviral treatmentHIV-positiveCross-sectional designSystemic disease
2013
Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection
Price RW, Peterson J, Fuchs D, Angel TE, Zetterberg H, Hagberg L, Spudich S, Smith RD, Jacobs JM, Brown JN, Gisslen M. Approach to Cerebrospinal Fluid (CSF) Biomarker Discovery and Evaluation in HIV Infection. Journal Of Neuroimmune Pharmacology 2013, 8: 1147-1158. PMID: 23943280, PMCID: PMC3889225, DOI: 10.1007/s11481-013-9491-3.Peer-Reviewed Original ResearchConceptsHIV infectionCentral nervous system infectionSystemic HIV infectionNervous system infectionCNS disease progressionCerebrospinal fluid biomarkersCross-sectional studyInteraction of HIVCSF biomarker studiesCNS infectionsDisease activitySystem infectionAntiretroviral treatmentClinical stagingNeural injuryCSF biomarkersNeurological consequencesFluid biomarkersDisease progressionMore accurate diagnosisNeuropsychological test performanceNovel biomarkersAccurate diagnosisBiomarker concentrationsInfection
2011
Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden
Spudich S, Gisslen M, Hagberg L, Lee E, Liegler T, Brew B, Fuchs D, Tambussi G, Cinque P, Hecht FM, Price RW. Central Nervous System Immune Activation Characterizes Primary Human Immunodeficiency Virus 1 Infection Even in Participants With Minimal Cerebrospinal Fluid Viral Burden. The Journal Of Infectious Diseases 2011, 204: 753-760. PMID: 21844301, PMCID: PMC3156103, DOI: 10.1093/infdis/jir387.Peer-Reviewed Original ResearchConceptsWhite blood cell countCSF HIV RNAPrimary HIV infectionHIV RNACerebrospinal fluidPHI participantsImmune activationAlbumin ratioPrimary human immunodeficiency virus-1 infectionCentral nervous system immune activationCSF white blood cell countHuman immunodeficiency virus-1 (HIV-1) infectionHuman immunodeficiency virus (HIV) infectionHigher albumin ratioHIV-seronegative controlsImmunodeficiency virus infectionHIV-seronegative participantsCells/μLLow cerebrospinal fluidBlood cell countVirus-1 infectionCross-sectional studyMagnitude of infectionCXCL10 concentrationsPHI patients
2009
Amyloid and tau cerebrospinal fluid biomarkers in HIV infection
Gisslén M, Krut J, Andreasson U, Blennow K, Cinque P, Brew BJ, Spudich S, Hagberg L, Rosengren L, Price RW, Zetterberg H. Amyloid and tau cerebrospinal fluid biomarkers in HIV infection. BMC Neurology 2009, 9: 63. PMID: 20028512, PMCID: PMC2807422, DOI: 10.1186/1471-2377-9-63.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAIDS Dementia ComplexAIDS-Related Opportunistic InfectionsAlzheimer DiseaseAmyloid beta-PeptidesAmyloid beta-Protein PrecursorAnalysis of VarianceBiomarkersCross-Sectional StudiesFemaleHIV InfectionsHIV-1HumansMaleMiddle AgedPeptide FragmentsPrincipal Component AnalysisTau ProteinsConceptsAIDS dementia complexCerebrospinal fluid biomarkersOpportunistic infectionsADC patientsAlzheimer's diseaseHIV infectionP-tauDisease patientsFluid biomarkersCentral nervous system opportunistic infectionsSoluble amyloid precursor protein alphaLower CSF Aβ1-42CSF t-tau levelsCNS immune activationCNS opportunistic infectionsCSF p-tauCSF t-tauT-tau levelsCross-sectional studyCSF Aβ1-42Alzheimer's disease patientsUninfected subjectsInfection patientsNeural injuryNeurological symptoms